Subsequent line of therapy after nilotinib cessation
| Therapy . | No. of patients . | Median total time on nilotinib, mo . | Molecular response at time of nilotinib cessation . | Progress at 6 mo after cessation of nilotinib . |
|---|---|---|---|---|
| Imatinib | 3 | 16 | MR3.0 (n = 2) | Maintained MMR (n = 3) |
| MR4.5 (n = 1) | ||||
| Dasatinib | 11 | 30 | MR2.0 (n = 2) | Maintained or attained MMR (n = 10) |
| MR3.0 (n = 1) | ||||
| MR4.0 (n = 2) | Resistance to second TKI (n = 1) | |||
| MR4.5 (n = 6) | ||||
| No TKI | 5 | 34 | MR3.0 (n = 1) | Died of other cause (n = 1) |
| MR4.5 (n = 4) | Maintained MR4.5 (n = 4) |
| Therapy . | No. of patients . | Median total time on nilotinib, mo . | Molecular response at time of nilotinib cessation . | Progress at 6 mo after cessation of nilotinib . |
|---|---|---|---|---|
| Imatinib | 3 | 16 | MR3.0 (n = 2) | Maintained MMR (n = 3) |
| MR4.5 (n = 1) | ||||
| Dasatinib | 11 | 30 | MR2.0 (n = 2) | Maintained or attained MMR (n = 10) |
| MR3.0 (n = 1) | ||||
| MR4.0 (n = 2) | Resistance to second TKI (n = 1) | |||
| MR4.5 (n = 6) | ||||
| No TKI | 5 | 34 | MR3.0 (n = 1) | Died of other cause (n = 1) |
| MR4.5 (n = 4) | Maintained MR4.5 (n = 4) |
MMR, major molecular response.